Whalesbook
Dr. Reddy's Laboratories is set to report a sharp year-on-year decline in earnings for the March 2026 quarter (Q4FY26). This financial picture is shaped by significant challenges in the US market, contrasted with strong performance in its domestic business. While overall results may show a contraction, investors are looking at the company's strategic moves and emerging growth drivers.
US Market Pressure Continues
Analysts forecast a significant 34% year-on-year drop in net profit, estimated at ₹1,035 crore, with revenue expected to fall 3.35% to ₹8,220 crore for Q4FY26. Earnings Before Interest, Tax, Depreciation, and Amortisation (Ebitda) are projected to decrease by over 20% to ₹1,629 crore. The primary driver for this downturn is the steep expected drop in North American revenues, with some analysts forecasting a 33% quarter-on-quarter decline. This is largely due to the phasing out of generic Revlimid as its patent exclusivity ends, bringing US business profitability back to pre-Revlimid levels. Additional pressure comes from rising freight costs, amplified by global geopolitical tensions.
India Business Drives Growth
In contrast to US market challenges, Dr. Reddy's domestic business is performing strongly, with projections for double-digit growth of 15% to 18% year-on-year. This strength is boosted by growth in key treatment areas and the successful integration of acquired product lines. The overall Indian pharmaceutical market also showed robust momentum, achieving 10.5% value growth in Q4 FY26, its highest in five quarters, largely driven by treatments for chronic conditions. A strategic development is the March launch of 'Obeda,' its generic semaglutide injection approved by India's drug regulator, which is expected to contribute to current quarter earnings and accelerate growth in fiscal year 2027. The company is also emphasizing its biosimilar pipeline and progress on GLP-1 approvals as vital for future revenue streams.
Stock and Valuation Metrics
The company has a market capitalization of approximately $11 billion. Its trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio is around 17-18x, which is lower compared to peers like Sun Pharmaceutical Industries (around 36.7x). Dr. Reddy's stock has seen a year-to-date decline of about 5.77% in 2026. Analyst sentiment is generally mixed, with a consensus rating of 'Hold', and projected 12-month price targets averaging between $14.29 and $16.90 USD, indicating potential for moderate upside according to some analysts.
Key Risks and Challenges
The expiry of patents, especially for Revlimid, is significantly impacting US generics revenue for Dr. Reddy's and competitors such as Cipla and Zydus Lifesciences. Despite new product launches, concerns remain about the company's ability to scale these therapies and secure timely regulatory approvals in key markets. The US generics market is expected to continue facing intense price competition. Additionally, Brazil's ANVISA rejected the company's diabetes and weight loss drug 'Embeltah' due to technical issues, raising questions about regulatory navigation for new drugs. Rising freight and input costs from global geopolitical events are also affecting margins, a challenge faced across the Indian pharmaceutical sector. An operational hurdle also arises from a significant penalty imposed by Russian tax authorities for VAT charges.
Future Outlook and Growth Catalysts
Investors will be watching the progress of Dr. Reddy's biosimilar pipeline and its GLP-1 drug approvals as key drivers for future growth. The company's success in counteracting current US revenue pressures with new launches over the next 12 to 18 months will be crucial. Morgan Stanley recently reduced its earnings estimates for Dr. Reddy's FY26, citing the Revlimid phase-out and uncertainty around GLP-1 drugs. However, the firm expects margins to improve from FY28 onward, supported by semaglutide and biosimilar sales. Dr. Reddy's is scheduled to report its Q4 FY26 results on May 12, 2026.